MedTrace Logo

Recombinant Human Serum Albumin/Granulocyte Colony Stimulating Factor Fusion Protein for Breast Cancer Patients

NCT03251768 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2019-09-13

No results posted yet for this study

Summary

Evaluation of the efficacy and safety of recombinant human serum albumin / granulocyte-stimulating factor fusion protein for injection to prevent chemotherapy-induced neutropenia

Conditions

  • Chemotherapy-induced Neutropenia

Interventions

DRUG

rHSA-GCSF 2.4mg

Human Serum Albumin GCSF 2.4mg at day 3 and day 7

DRUG

GCSF

GCSF 5 mcg/kg/day

Sponsors & Collaborators

  • Tianjin SinoBiotech Ltd.

    lead INDUSTRY

Principal Investigators

  • Binghe XU, MD · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-19
Primary Completion
2018-07-23
Completion
2019-04-24

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03251768 on ClinicalTrials.gov